RecruitingPhase 2NCT06982963
Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease
Studying ADULT syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Forte Biosciences, Inc.
- Intervention
- FB102(biological)
- Enrollment
- 100 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- The Royal Melbourne Hospital, Melbourne, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06982963 on ClinicalTrials.govOther trials for ADULT syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07237750iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight LossLiu Yan
- ACTIVE NOT RECRUITINGNANCT07258615Longitudinal Ultrasound Assessment of Diaphragmatic and Respiratory Muscle Function Following Respiratory Muscle Training in Frail Older AdultsUniversidad Francisco de Vitoria
- RECRUITINGNANCT07343206Early Norepinephrine Administration and Rapid Dose AdjustmentSiriraj Hospital
- RECRUITINGPHASE3NCT07225686Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyAmgen
- RECRUITINGPHASE3NCT07284381A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye DiseaseAbbVie
- RECRUITINGNANCT07303452Evaluation of the Restera™ Serene™ System in Adults With Obstructive Sleep ApneaRestera, Inc.
- RECRUITINGNCT07043166Cardiovascular-Kidney-Metabolic Syndrome in Shanghai ZicitizensShanghai Changzheng Hospital
- RECRUITINGPHASE4NCT06184659Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With SepsisScandinavian Critical Care Trials Group